Active substancePyrazinamidePyrazinamide Similar drugsTo uncover Linamide pills inwards FARMGID CJSC Russia Macroside® pills inwards McLeodz Pharmaceuticals Co., Ltd. India Pisina pills inwards Lupine Co., Ltd. India Pyrazinamide pills inwards VALENTA PHARM, PAO Russia Pyrazinamide pills inwards FORTYUN MED, LTD Russia Pyrazinamide pills inwards ROSFARM, LLC Russia Pyrazinamide pills inwards OZONE, LLC Russia Pyrazinamide pills inwards NORTH STAR, CJSC Russia Pyrazinamide pills inwards FARMSINTEZ, PAO Russia Pyrazinamide STADA pills inwards NIZHFARM, JSC Russia Pyrazinamide-Acry® pills inwards AKRIKHIN HFK, JSC Russia Pyrazinamide-NIKA pills inwards NIKK, CJSC Russia Pirafat pills inwards Rimzer Artsynaimitel, AG Germany Dosage form: & nbspPills. Composition:Each tablet contains:Active substance: pyrazinamide (Br.F.) 500 mg.Excipients: calcium phosphate disubstituted, dihydrate, pregelatinized starch, corn starch, silicon dioxide colloidal, sodium lauryl sulfate, magnesium stearate, talc purified. Description:White round, flat tablets with beveled edges, with the inscription "RΥΖIΝΑ LUPIN" and a dividing notch on one side. Pharmacotherapeutic group:Anti-tuberculosis drug. ATX: & nbspJ.04.A.K.01 Pyrazinamide Pharmacodynamics:Has a bacteriostatic or bactericidal effect depending on the concentration and sensitivity of the microorganism. More active on tuberculostatic activity than paraaminosalicylic acid (PASK), although inferior to isoniazid, streptomycin, rifampicin. It operates on mycobacteria, resistant to other anti-tuberculosis drugs of the II series.The drug penetrates well into the centers of tuberculous lesion. Its activity does not decrease in the acidic environment of caseous masses, and therefore it is often prescribed for caseous lymphadenitis, tuberculomas and caseous-pneumonic processes. Pharmacokinetics:Pyrazinamide well absorbed from the digestive tract. After oral administration of a dose of 500 mg to adults, the peak concentration of pyrazamide in blood plasma within 9-12 μg / ml is achieved within 2 hours, 7 μg / ml after 8 hours and 2 μg / ml after 24 hours. Pyrazinamide penetrates the tissues and body fluids, including the liver, lungs, cerebrospinal fluid. Approximately 50% binds to plasma proteins. The half-life is 9-10 hours in those patients whose liver and kidney function are not impaired.Within 24 hours, about 70% of the oral dose is excreted by the kidneys. About 4-14% of the dose is released unchanged. The residues are excreted as metabolites. Indications:Apply the drug with a therapeutic purpose for the appointment of a doctor for tuberculosis. In combination with other anti-tuberculosis drugs are prescribed in the following cases:- pulmonary tuberculosis;- tuberculous meningitis;- tuberculosis of bones;tuberculosis of urogenital organs. Contraindications:- individual intolerance;- liver disease;- gout;- Hyperuricemia;- Pregnancy, lactation. Dosing and Administration:The drug is used inside during or after a meal, once a day, preferably at breakfast with a little water.Adults appoint 25-30 mg / kg body weight, which corresponds to those with a body weight of less than 50 kg - 1.5 g and for individuals with a body weight of more than 50 kg - 2 g.The maximum daily dose is 2.5 g.In case of unsatisfactory portability, Pisina is prescribed in 2-3 sessions.In elderly and elderly people, the daily dose of pyrazinamide should not exceed 15 mg / kg of body weight. In these cases, the drug should be administered every other day.Children are prescribed 15-20 mg / kg once a day (maximum to 1.5 g per day).Pyrazinamide is used in combination with aminoglycosides (streptomycin or kanamycin in a dose of 15 mg / kg), isoniazid (10 mg / kg), rifampicin (10 mg / kg).The course of treatment is 3 months. Side effects:On the part of the digestive system: nausea, vomiting, diarrhea, impaired liver function (anorexia, pain in the right hypochondrium, hepatomegaly, jaundice, yellow atrophy); exacerbation of peptic ulcer.On the part of the genitourinary and urinary system: dysuria, interstitial nephritis.From the musculoskeletal system: arthralgia, myalgia.From the system hemostasis system and hematopoiesis: splenomegaly, anemia.Allergic reactions: skin rash, hives, photosensitivity.Other: fever, hyperuricemia, exacerbation of gout, increased serum iron concentration. Overdose:Symptoms: a violation of the liver. Treatment is symptomatic. Interaction:Pyrazinamide are combined with other antituberculosis drugs. In particular, with chronic destructive forms it is recommended to combine it with rifampicin (pronounced effect) or ethambutol (better tolerability).The likelihood of developing a hepatoxic effect of the drug is increased when combined with rifampicin. Possible development of hypoglycemia in patients with diabetes. With simultaneous application with probenecid, a decrease in excretion and, consequently, an increase in toxic reactions is possible. Special instructions:There is evidence of a delay in the body under the influence of pyrazinamide uric acid, which can lead to the appearance of gouty arthritic pains in the joints. Therefore, it is advisable to monitor the activity of hepatic transaminases and the content of uric acid in the blood regularly (at least once a month).With prolonged use may have toxic effects on the liver. Packaging:For 10 tablets in a blister of PVC-aluminum foil. For 10 blisters with instructions for use in a pack of cardboard box.For 100 tablets in a plastic bag, which is placed in a plastic container along with instructions for use. Storage conditions:List B. Store in a dry place inaccessible to children, at a temperature of no higher than 30 ° C. Shelf life:5 lay down.Do not use after the expiry date printed on the package. Terms of leave from pharmacies:On prescription Registration number:П N014933 / 01-2003 Date of registration:25.03.2009 The owner of the registration certificate:Lupine Co., Ltd.Lupine Co., Ltd. India Manufacturer: & nbspLUPIN, Ltd. India Information update date: & nbsp30.07.2015 Illustrated instructions × Illustrated instructions Instructions